FDA will reverse rejection of Regenxbio rare-disease drug.
The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio. The Wall Street Journal reported the exclusive on Monday, June 22, 2026.
0
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Wall Street Journal
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
Wall Street Journal
Exclusive | FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
exclusive investigative report · positive
Reuters
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
attribution to WSJ · neutral
First to report
- Reutersfirst
- Wall Street Journal+6.5 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
WSJ broke the story as an exclusive on the reversal. Reuters simply attributed the report to WSJ without independent confirmation.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports”
“Exclusive | FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says”
3 tracked claims across 2 outlets
Fact ledger
All3Claimed3
2/2
Claimed
The FDA will reverse its earlier rejection of a Regenxbio rare-disease therapy.
Corroborated
Disputed
2 more tracked claimsSign up free to see the full ledger